PATENT CLAIM ANALYSIS

Application Number: 16033008
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["546", "111000"]

Abstract:
The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

Claim (Index 1):
A method of treating obesity and/or diabetes I or II (preferably obesity and diabetes II) in a patient in need comprising administering to said patient an effective amount of a modulator of the G protein-coupled estrogen receptor (GPER/GPR30), wherein said modulator is a compound according to the chemical structure

Metadata:
- Claim Count in Document: 7.0
- Percentile: 95.0
- Lexical Diversity: 1.53846
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15556055', '13652187', '15667737', '15747697', '14888390']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6875506277608583
- 35 USC 102 Novelty (BERT): 0.5869644527484962
- Combined Prediction Score: 0.6774920102596221
- Mean Citation Score: 281.99261
- Max Citation Score: 582.18835
- Similarity Product: 377.0991207359792

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test